The expression of VEGFR-2 varied in different OSA cell lines and tumors [8,69], which suggests the potential of using toceranib in patients with overexpressed VEGFR-2, as well as the significance of individual targeted therapy. Here, KDR is linked to obstructive sleep apnea syndrome.